differences in study populations, diagnostic assessment, and disease definitions. [4] [5] [6] This study reports the results of systematic family screening of CASPER probands using sequential cardiac investigations in conjunction with phenotype-directed genetic testing. We also compared the diagnostic yield of systematic assessment between relatives of UCA survivors and relatives of SUD victims.
Methods Patients
The CASPER is a national registry including patient data from 14 Canadian centers. Since January 2004, the registry prospectively enrolls survivors of UCA (documented ventricular fibrillation or pulseless ventricular tachycardia [VT] ) and their first-degree family members (siblings, parents, or children of proband), as well as firstdegree relatives of victims of SUD with negative autopsy and toxicology screening. SUD was defined as sudden cardiac death without evidence of structural heart disease after autopsy including normal toxicology screening and the absence of clinical features suggestive of other pathogeneses. 7 Sudden cardiac death was defined as previously published describing unexplained death within 1 hour after the onset of witnessed symptoms or within 24 hours from the moment when the decedent was last seen alive in the absence of symptoms (unwitnessed) or any obvious noncardiac causes. 8 Details of the protocol and eligibility criteria have been described previously. 9 Patients are excluded in the presence of any of the following: (1) resting ECG with corrected QTc >460 ms (men) or >480 ms (women); (2) presence of a coronary artery stenosis >50% or anomalous coronary arteries; (3) evidence of hypertrophic cardiomyopathy on imaging; (4) presence of type I Brugada ECG in leads V 1 or V 2 , 10 (5) left ventricular ejection fraction <50% that was not transient and related to resuscitation, (6) hemodynamically unstable VT because of idiopathic VT.
Individuals in the present study were enrolled from January 2004 to January 2015. All individuals provided written informed consent. The study protocol was approved by the local ethics and research board of each participating center. The protocol was registered at www.ClinicalTrials.gov (NCT00292032-Registry of Unexplained Cardiac Arrest).
Cardiac Investigations
Individuals underwent comprehensive cardiac testing to screen for structural heart disease or inherited arrhythmia. The diagnostic workflow is shown in Figure 1 . Cardiac workup included a detailed history, resting ECG with standard and high precordial leads, 11 symptom-limited exercise testing, ambulatory Holter monitoring, signal averaged ECG, and transthoracic echocardiogram. Cardiac magnetic resonance imaging, coronary angiogram, and pharmacological provocation with procainamide and epinephrine were performed in selected patients based on clinical suspicion and patient preference.
Symptom-limited exercise testing was performed with a modified or standard Bruce protocol. A positive exercise test for Long-QT (LQT) syndrome was defined as end recovery corrected QT >455 ms based on a validated algorithm (4-6 minutes into recovery). 12, 13 QT assessment was performed according to the maximal slope technique using lead V5 or lead II. 14 Recording and interpretation of signal averaged ECGs were performed according to published criteria. 15 Drug challenge with procainamide and epinephrine was performed as previously described. 11, 16 Cardiac abnormalities were defined as new diagnosis of a previously unknown primary electric disorder (eg, LQT syndrome or Brugada syndrome), a new diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) or as new diagnosis of another previously unknown structural heart disease (eg, hypertrophic cardiomyopathy, myocarditis, cardiac sarcoidosis, etc.). Diagnostic criteria for LQT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), ARVC, and ERS were based on current guidelines. [17] [18] [19] 
Genetic Testing
Targeted genetic testing was performed on the basis of phenotype detection in patients after systematic clinical testing. Genetic testing was performed on suspected culprit genes using largely commercial genetic testing based on the clinically supported panel at the time of testing (for Long-QT syndrome, minimum genes tested were as follows: KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2; for Brugada syndrome: SCN5A; for ARVC: Pkp2 and Dsp; and for CPVT minimum exons tested were as follows: RyR2 selected exons 2-4, 6-15, 17-20, 39-49, 83, 84, 87-97, and 99-105).
Diagnostic Strength
All clinical diagnoses were reevaluated at the time of study follow-up, and investigators indicated whether these diagnoses were based on phenotype alone, genotype alone, or both. Based on the weight of evidence from context of symptoms, family history, and the results of clinical and genetic testing, the working diagnosis was further classified using a qualitative descriptor of the strength of the diagnosis as definite, probable, and possible. The definitions of the levels of strength are reported in Table 1 and were published previously. 2 The working diagnosis could be revised over time on the basis of events during follow-up or new evidence from repeated clinical or genetic testing.
Predictors of Cardiac Abnormalities
First-degree relatives with a new diagnosis of a primary electric disorder or previously unknown structural heart disease were screened for clinical predictors to detect cardiac abnormalities after systematic stepwise assessment. Prespecified clinical predictors included male sex, age <45 years, a personal history of syncope and Asian ethnicity.
Statistical Analysis
Continuous data are expressed as mean±SD or as median and interquartile range depending on normal or skewed data distribution. Categorical variables are expressed as absolute number and percentage. Fisher exact test or χ 2 -test was used for
WHAT IS KNOWN
• A significant proportion of unexplained cardiac arrest/sudden unexplained death is caused by previously undiagnosed inherited arrhythmias placing other family members at risk.
• Although screening of first-degree relatives of unexplained cardiac arrest and sudden unexplained death victims is recommended, the diagnostic yield is heterogeneous in previous studies. It is also unclear if the same diagnostic approach should be used for family members of unexplained cardiac arrest survivors and sudden unexplained death victims respectively.
WHAT THE STUDY ADDS
• Applying a systematic, stepwise, phenotype-directed approach reveals cardiac abnormalities in 30% of first-degree family members with a high degree of diagnostic certainty. analyses were conducted using the SPSS software version 22 (SPSS Inc., Chicago).
Results
A total of 398 first-degree relatives of UCA patients or SUD victims were enrolled in the study. The median number or first-degree relatives per proband was 2 (interquartile range, 1) without differences between UCA survivors or SUD victims. Baseline characteristics of the study population are outlined in Table 2 and Figure I in the Data Supplement. Cardiac symptoms at the moment of enrollment are outlined in Table 3 . Overall, 18% of all family members had a history of syncope or presyncope. The diagnostic evaluation outcome is summarized in Table 4 . Overall, the average number of different tests per individual was significantly higher in firstdegree relatives of SUD victims compared with relatives of UCA survivors including advanced cardiac imaging and provocative testing.
Diagnostic Yield
Cardiac abnormalities were found in 120 of 398 patients (30%) with 67 of 398 (17%) having a definite or probable diagnosis ( Figure 2A ). The proportion of affected family members was similar in first-degree relatives of UCA survivors and SUD victims (32% [59/186] versus 29% [61/212]; P=0.59). The degree of diagnostic certainty was equally distributed between the 2 groups of family members ( Figure 2B ). The most common abnormality was LQT syndrome (13%) followed by CPVT (4%), ARVC (4%), and Brugada syndrome (3%, Figure 3 ). The distribution of cardiac abnormalities was similar between the relatives of UCA survivors and SUD victims. Detailed analysis of signal averaged ECG data did not show any difference between relatives of UCA survivors or SUD victims ( Table 1 in the Data Supplement).
Results of Pharmacological Drug Challenge
Pharmacological provocation with epinephrine or procainamide was performed in 24% (96/398) and 19% (77/398) of all family members, respectively. The results are outlined in Tables 2 and 3 in the Data Supplement. Abnormal results of epinephrine challenge were found in 17% with 14% suggestive of LQT syndrome and 3% suggestive of CPVT. Detailed reporting of epinephrine challenge results for the entire study has been reported previously. 20 The distribution of test results was similar between family members of UCA survivors and SUD victims. With regard to procainamide challenge, 8% (6/77) patients had an inducible type I Brugada pattern with similar distribution between the 2 groups. The diagnostic yield of procainamide provocation in first-degree relatives was similar to the yield obtained in UCA survivors. 11
Genetic Testing
Genetic testing was performed in 96 of 398 patients (24%; Table 5 ). Family members of SUD victims underwent genetic testing more frequently (29% versus 20%; P=0.03), and molecular autopsy had not been performed in the majority of SUD victims. Disease-causing mutations were identified in 20 of 398 family members (21% of those tested). The most common pathogenic mutations were RyR2 (2.3%), SCN5A (1%), and KNCQ1 (0.8%). The overall percentage of clinically affected family members with a correlated positive genotype was 4% (N=17, 18% of those tested). The yield of genetic testing in first-degree relatives with a definite or probable diagnosis of inherited arrhythmia was 34% (17/51), and the phenotypegenotype correlation for LQT syndrome, CPVT, Brugada syndrome, and ARVC was 12%, 75%, 22%, and 75%, respectively ( Figure 4 ).
Of note, 3 pathogenic mutations were found in phenotype-negative family members (0.8%). Two asymptomatic relatives of UCA survivors were carriers of a likely diseasecausing SCN5A mutation (both F1210S), and another patient was an unaffected carrier of a pathogenic PKP2 mutation (D26N). The yield of genetic testing was similar for family members of UCA survivors or SUD victims (3% versus 2%; P=0.15; Table 5 ). 
Follow-Up and Clinical Outcome
Follow-up was offered to all first-degree family members independent of their diagnostic status. The median followup duration was 24 months (interquartile range, 36 months) and was similar for family members of UCA and SUD victims (Table 6 ). Overall, 42% of first-degree relatives did not undergo long-term follow-up after initial assessment. Family members without follow-up data typically represented individuals without the evidence of cardiac abnormalities after clinical and genetic testing (68% of UCA relatives versus 78% of SUD relatives; P=0. 16) . Cardiac symptoms during follow-up are displayed in Table 6 . There was no cardiac arrest or sudden cardiac death in first-degree relatives. No cardiac symptoms were observed in family members without a final diagnosis after stepwise assessment. A total of 6% experienced likely cardiac syncope or presyncope and 9% underwent implantable cardioverter defibrillator (ICD) implantation for primary prevention. Most common underlying diagnosis in family members undergoing ICD implantation was LQT syndrome (27%) followed by CPVT and Brugada syndrome (15% each).
Predictors of Cardiac Abnormalities
We performed an analysis of factors that predict detection of abnormalities after systematic stepwise screening. Table 7 shows the univariate analysis of potential predictors increasing the likelihood of finding cardiac abnormalities in firstdegree relatives of UCA/SUD victims. The only significant predictor was a personal history of prior unexplained syncope (odds ratio, 2.42; 95% control interval, 1.28-4.57; P=0.007).
Discussion
This multicenter prospective study demonstrates that a systematic approach including noninvasive cardiac assessment and selected genetic testing can uncover a causative pathology in a large proportion of first-degree relatives of UCA survivors or SUD victims. Cardiac abnormalities were found in 30% of screened family members with 17% of them having a definite or probable diagnosis. Primary electric disorders (LQT syndrome, CPVT, and Brugada) or ARVC accounted for the majority of diagnoses (73%). The overall diagnostic yield and distribution of inherited arrhythmia in our study is comparable to previous reports with smaller populations. [21] [22] [23] Other screening studies of family members have shown diagnostic yields varying from 18% to 62%, which might be explained by different inclusion criteria of the studied population as well as differences in the diagnostic protocols. [4] [5] [6] For example, the study by Kumar et al 6 (n=502) included in contrast to CASPER first-and second-degree family members of SUD and UCA victims and enrolled significantly more family members of SUD victims. The diagnostic yield in SUD 
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Definite P robable P ossible p = 0.18 p = 0.55 p = 0.61 relatives was only 18% compared with 62% in relatives of UCA survivors. 6 The CASPER registry is characterized by specific exclusion criteria including the evidence of moderate structural disease or overt primary electric disorder by the time of the index event. 2 Another distinctive feature is our systematic classification of the diagnostic strength with the intention to ensure a high level of diagnostic standardization and reproducibility.
The key element for the high diagnostic yield in our study population was the application of a systematic stepwise phenotype-directed approach. 2, 9 As a result, we observed no difference in the diagnostic yield between first-degree relatives of UCA survivors and SUD victims. Family members of SUD victims underwent more extensive clinical testing, which reflects the undifferentiated phenotype in the corresponding proband.
In contrast to our findings, the study by Kumar et al reported a low diagnostic yield of only 18% in the family members of SUD victims. 6 Several reasons might account for this, including an overall low-risk population, screening of seconddegree family members, and underutilization of functional, provocative testing (only 10% with pharmacological challenge compared with 33% in our cohort). The diagnostic utility of provocative pharmacological tests in patients with UCA is well established. 9, 11, 20 The results in first-degree relatives were comparable to the diagnostic yield of pharmacological drug 12 challenge in CASPER probands suggesting a higher proportion of false-positive test in our study population.
Genetic screening for disease-causing mutations in the context of inherited arrhythmia is part of a comprehensive assessment, but should never be considered as a stand-alone approach. Even in index patients with a frank phenotype, the diagnostic yield of genetic testing with next generation sequencing is still highly variable, with positive results in 20 to 75% of cases depending on the underlying electric disorder. 24 In the initial cohort of CASPER probands, 30% of patients underwent genetic testing with a diagnostic yield of 47%. 2 In this study, 24% of the enrolled family members underwent targeted genetic testing based on the results of noninvasive cardiac assessment. We found a phenotype-genotype correlation in 34% of screened family members with a definite or probable diagnosis. Previous studies reported genotypephenotype correlations of 35% to 59% in relatives of UCA/ SUD victims. 6, 22 However, differences in study populations and the extent of screened genes as well as potential selection bias make it difficult to compare those studies.
Overall, our results suggest that phenotype-directed genetic testing has similar utility for family members of UCA survivors. The phenotype-genotype correlation for patients with definite or probable Brugada syndrome, CPVT, or ARVC in our study was consistent with contemporary literature, whereas the proportion of gene positive LQT patients was lower than previously described. 24, 25 Older studies reported positive genetic findings in up to 78% of patients with a clear LQT phenotype. 26 However, those data were derived from highly selected patients with overt LQT syndrome and high Schwartz scores. 26 By default, LQT phenotypes in our study population were subtler and in some cases solely based on a positive epinephrine test that is limited by a false-positive rate of up to 20%. 20 In addition, most gene-negative LQT patients were enrolled early after the start of the CASPER registry and significant improvements in genetic sequencing over time might partially account for the low yield of LQT mutations. Revisiting clinical genetic testing in these subjects is driven by local clinical practice, with costs likely representing the biggest barrier to broader gene screening.
The likelihood of a cardiac abnormality in our study was not influenced by age, sex, or ethnicity. The only useful predictor was a personal history of prior unexplained syncope that increased the likelihood of a final diagnosis >2-fold. Our results are consistent with a previous study that also identified syncope of first-degree relatives as a predictor for a diagnosis of inherited arrhythmia. 4 This also emphasizes the importance of a detailed history, which is an integral part of our stepwise protocol. Another study suggested age under 40 of SUD victims to be a predictor of cardiac abnormalities in first-degree relatives; however, this might be strongly influenced by the type of inherited arrhythmia and individual risk profile. 22 The overall clinical outcome in our study was favorable, and there was no cardiac arrest during a limited follow-up period. Nevertheless, a small proportion of family members experienced cardiac syncope over time leading to ICD implantation or adjustment of medication, which emphasizes the importance of long-term follow-up. We did not observe a prognostic difference in family members of UCA survivors or SUD victims, but the study was not designed for this purpose and was underpowered because of a small number of events. Overall, our observations are somewhat reassuring and demonstrate that most first-degree relatives with a new diagnosis of cardiac abnormalities are at low risk for future arrhythmic events.
In summary, our data demonstrate that a systematic stepwise diagnostic approach with phenotype-directed genetic testing is also useful to first-degree family members of survivors of UCA or SUD victims and reveals strong evidence of a diagnosis in 1 in 6 patients, and a suggestive diagnosis in a further 1 in 6.
Limitations
Inherited arrhythmias are uncommon diseases that making it challenging to study larger cohorts. Nonetheless, we present a large population with all individuals being prospectively enrolled in a multicenter registry (CASPER). All patients of this study are highly selected because the different CASPER sites are tertiary referral centers. This selection/referral bias may not reflect the yield of testing in community hospitals and clinics. The overall percentage of genetic testing performed in our study was relatively low and raises the question of whether a broader approach would have resulted in a higher diagnostic yield. On the other hand, genetic testing is costly and requires judicious use in a public healthcare system. The CASPER registry achieves this by its stepwise algorithm with phenotypedirected clinical genetic testing at the end of the diagnostic workup. Also, the results of broad genetic testing can rarely be interpreted on a stand-alone basis and are discouraged by guidelines in the absence of a phenotype in part because of the frequent detection of variants of unknown significance. 17, 27, 28 The patients in our study were enrolled over a period of 10 years and the relatively low absolute number of pathogenic mutations may reflect earlier sequencing techniques and scope. Nonetheless, our results show that phenotype-directed genetic testing results in a reasonable genotype-phenotype correlation that is comparable to other published studies.
Conclusion
Systematic stepwise cardiac assessment reveals cardiac abnormalities in almost a third of first-degree relatives of UCA survivors or SUD victims. LQT syndrome, CPVT, and ARVC were the most common diagnoses with a phenotype-genotype correlation of 34%. Systematic cascade screening and genetic testing in asymptomatic relatives is useful, providing potentially explanatory diagnostic results despite absent or subclinical phenotype in the index patient. Our approach helps to identify individuals potentially at risk. Early detection helps to establish preventive lifestyle modifications and medical interventions with the potential to prevent sudden cardiac death. 
